FIGURE 4.

Comparison of observed and predicted pharmacodynamic responses to MEDI1814 after administration to patients with AD. Data show median % change from baseline in CSF free Aβ₄₂ after administration of placebo and MEDI1814 single doses (25, 100, 300, 900, and 1800 mg IV or 100 mg SC in the single ascending dose study [A]) or repeat doses (300, 900, and 1800 mg IV or 200 mg SC, administered monthly in the multiple ascending dose study [B]). Relative to baseline, a dose‐dependent reduction of free Aβ₄₂ in CSF and increase in total (bound and free) Aβ₄₂ was observed at day 29 after single MEDI1814 doses (A). Near maximal levels of suppression were observed after the 900 and 1800 mg IV repeat doses (B). Aβ, amyloid beta; AD, Alzheimer's disease; CSF, cerebrospinal fluid; assay; IV, intravenous; SC, subcutaneous.